Loading...

Brilliant Violet 421™ anti-mouse CD127 (IL-7Rα) Antibody

Pricing & Availability
Clone
A7R34 (See other available formats)
Regulatory Status
RUO
Other Names
IL-7 receptor α chain, IL-7Rα
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
A7R34_BV421_1_040311
C57BL/6 mouse splenocytes were stained with CD3ε FITC and CD127 (clone A7R34) Brilliant Violet 421™ (top) or rat IgG2a, κ Brilliant Violet 421™ isotype control (bottom).
  • A7R34_BV421_1_040311
    C57BL/6 mouse splenocytes were stained with CD3ε FITC and CD127 (clone A7R34) Brilliant Violet 421™ (top) or rat IgG2a, κ Brilliant Violet 421™ isotype control (bottom).
  • A7R34_BV421_2_040311
See Brilliant Violet 421™ spectral data
Cat # Size Price Quantity Check Availability Save
135023 125 µL £148
Check Availability


Need larger quantities of this item?
Request Bulk Quote
135027 50 µg £166
Check Availability


Need larger quantities of this item?
Request Bulk Quote
135024 500 µL £283
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD127 is a 60-90 kD type I transmembrane glycoprotein also known as IL-7 receptor α chain or IL-7Rα. It forms a heterodimer with the common γ chain (γc or CD132) which is shared with the receptors for IL-2, IL-4, IL-9, IL-13, IL-15, and IL-21. CD127 is expressed on immature B cells through early pre-B stage, thymocytes (except CD4/CD8 double positive thymocytes), peripheral T cells, and bone marrow stromal cells. CD127 has been reported to be an useful marker for identifying memory and effector T cells. The ligation of IL-7 with its receptor is important for stimulation of mature and immature T cells as well as immature B cells proliferation and development.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
IL-7Ra-IgG1 fusion protein
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For immunofluorescent staining using µl sizes, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

A7R34 is able to block clone SB/199 binding to IL-7R.

Additional Product Notes

View more applications data for this product in our Scientific Poster Library.

Application References

(PubMed link indicates BioLegend citation)
  1. Sudo T, et al. 1993. P. Natl. Acad. Sci. USA 90:9125.
  2. Hashi H, et al. 2001. J. Immunol. 166:3702.
  3. Taylor R, et al. 2007. J. Immunol. 178:5659.
  4. Mazzon C, et al. 2011. Blood. 118:2733. PubMed
  5. Jin J, et al. 2011. J. Immunol. doi:10.4049/jimmunol.1001238. PubMed
Product Citations
  1. Nenasheva T, et al. 2017. PLoS One. 12(6):e0178983. PubMed
  2. Limbach K, et al. 2017. Malar J. 10.1186/s12936-017-1911-z. PubMed
  3. Fan MY et al. 2018. Cell reports. 25(5):1204-1213 . PubMed
  4. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  5. Michela Miani et al. 2018. Cell metabolism. 28(4):557-572 . PubMed
  6. Anderson CK et al. 2019. Cell Rep. 27(2):537-548 . PubMed
  7. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  8. Schmidleithner L et al. 2019. Immunity. 50(5):1232-1248 . PubMed
  9. Yue X, et al. 2019. Nat Commun. 10:2011. PubMed
  10. Shikatani EA et al. 2019. Cell Rep. 27(8):2304-2312 . PubMed
  11. Kumar MP, et al. 2018. Cell Rep. 25:1458. PubMed
  12. Toshiro Hirai et al. 2019. Immunity. 50(5):1249-1261 . PubMed
  13. Gagnon JD, et al. 2019. Cell Rep. 28:2169. PubMed
  14. Chopin M et al. 2018. Immunity. 50(1):77-90 . PubMed
  15. Ying Zhang et al. 2017. Cancer cell. 32(3):377-391 . PubMed
  16. Moguche AO et al. 2017. Cell host & microbe. 21(6):695-706 . PubMed
  17. Hiraishi Y, et al. 2018. Sci Rep. 8:18052. PubMed
  18. LaFleur MW, et al. 2019. Nat Immunol. 20:1335. PubMed
  19. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 0.252777778. PubMed
  20. Flamar AL, et al. 2020. Immunity. 52(4):606-619.e6.. PubMed
  21. He J, et al. 2020. Cell Reports. 29(9):2718-2730.e6.. PubMed
  22. Ma EH, et al. 2020. Immunity. 51(5):856-870. PubMed
  23. Zenke S, et al. 2020. Immunity. 52(2):313-327. PubMed
  24. Siegemund S, et al. 2015. PLoS One. 10:124661. PubMed
  25. Li B, Schmidt N 2016. PLoS One. 11: 0162427. PubMed
  26. Abdelsamed HA, et al. 2020. Nat Immunol. 1.276388889. PubMed
  27. Milner JJ, et al. 2020. Immunity. 52(5):808-824.e7. PubMed
  28. Hirai T, et al. 2020. Immunity. 54(1):84-98.e5. PubMed
  29. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  30. Dikiy S, et al. 2021. Immunity. 54(5):931-946.e11. PubMed
  31. McFarland AP, et al. 2021. Immunity. 54(6):1320-1337.e4. PubMed
  32. Huang X, et al. 2021. Immunity. . PubMed
  33. Wang X, et al. 2021. Immunity. 54(6):1123-1136.e8. PubMed
  34. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 5:64. PubMed
  35. Cha SE, et al. 2021. Oncoimmunology. 10:1899469. PubMed
  36. Lu YJ, et al. 2021. Cell Rep. 36:109696. PubMed
  37. Zong L, et al. 2021. NPJ Aging Mech Dis. 7:25. PubMed
  38. Lawson H, et al. 2021. Stem Cell Reports. 16:2784. PubMed
  39. Lee RD, et al. 2021. Nat Commun. 12:6843. PubMed
  40. Cassidy BR, et al. 2020. J Neuroinflammation. 17:259. PubMed
  41. Zhang Y, et al. 2021. J Immunol Res. 2021:5599439. PubMed
  42. Francian A, et al. 2021. J Drug Target. 29:754. PubMed
  43. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  44. Bergin SM, et al. 2021. Brain Behav Immun. 95:477. PubMed
  45. Waldman MM, et al. 2022. Front Immunol. 13:856977. PubMed
  46. Sasse C, et al. 2022. Pathogens. 11:. PubMed
  47. Uslu M, et al. 2020. J Cell Physiol. 235:9644. PubMed
  48. Sheldon RD, et al. 2021. Nat Protoc. 16:4494. PubMed
  49. Schloss MJ, et al. 2022. Nat Immunol. 23:605. PubMed
  50. Hackstein CP, et al. 2022. Nat Commun. 13:7472. PubMed
  51. Behr FM, et al. 2021. Eur J Immunol. 51:151. PubMed
  52. Parga-Vidal L, et al. 2022. Eur J Immunol. 52:1095. PubMed
  53. Campisi L, et al. 2022. Nature. 606:945. PubMed
  54. Backlund C, et al. 2022. Proc Natl Acad Sci U S A. 119:e2204078119. PubMed
  55. Wang W, et al. 2022. Cell Rep. 41:111582. PubMed
  56. Lin YH 2023. Immunity. 56(1):207-223.e8. PubMed
  57. Briukhovetska D, et al. 2023. Immunity. 56:143. PubMed
  58. Xu W 2023. Cell Reports. 42(1):111987. PubMed
  59. Xu R 2023. Cell Reports. 42(2):112054. PubMed
  60. Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed
  61. Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed
  62. Christian DA, et al. 2022. Sci Immunol. 7:eabq7432. PubMed
RRID
AB_10897948 (BioLegend Cat. No. 135023)
AB_2563103 (BioLegend Cat. No. 135027)
AB_11218800 (BioLegend Cat. No. 135024)

Antigen Details

Structure
Type I transmembrane glycoprotein, associate with CD132, 60-90 kD
Distribution

Immature B cells through early pre-B stage, thymocytes (except CD4/CD8 double positive thymocytes), peripheral T cells, bone marrow stromal cells

Function
T cell and immature B cell proliferation and development
Ligand/Receptor
IL-7
Cell Type
B cells, T cells, Thymocytes
Biology Area
Immunology
Molecular Family
CD Molecules, Cytokine/Chemokine Receptors
Antigen References

1. Sudo T, et al. 1993. P. Natl. Acad. Sci. USA 90:9125.
2. Okuno Y, et al. 2001. P. Natl. Acad. Sci. USA 99:6246.
3. Pillai M, et al. 2004. Leukemia Lymphoma 45:2403.

Gene ID
16197 View all products for this Gene ID
UniProt
View information about CD127 on UniProt.org

Related FAQs

What is the F/P ratio range of our BV421™ format antibody reagents?

It is lot-specific. On average it ranges between 2-4.

Go To Top Version: 1    Revision Date: 11/30/2012

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account